Ferric Gluconate Dosing: Hemodialysis vs Non-Dialysis CKD
For hemodialysis patients, administer 8 doses of 125 mg ferric gluconate over 8 weeks (total 1000 mg), while for non-dialysis CKD patients, give larger single infusions of 500-1000 mg due to practical limitations of requiring multiple clinic visits.
Hemodialysis Patients
The NKF-K/DOQI guidelines specifically recommend 8 doses of 125 mg ferric gluconate administered over 8 weeks for hemodialysis patients 1. This translates to:
- 125 mg per dialysis session (typically 3 times weekly)
- Total cumulative dose: 1000 mg over 8 weeks
- Each dose infused over 60 minutes 2
Alternatively, a lower-dose regimen of 8 doses of 62.5 mg over 8 weeks can be used, though this provides only 500 mg total and is less effective 1.
Important Caveats for Hemodialysis
- Do not exceed 125 mg per dose - the manufacturer does not recommend doses larger than 125 mg given at one time 1
- Maintenance dosing after initial repletion: 250-1000 mg within 12 weeks, administered as frequent smaller doses 1
- Monitor TSAT and ferritin every 3 months during maintenance 1
Non-Dialysis CKD Patients (Including Peritoneal Dialysis)
For non-dialysis CKD patients, the dosing strategy differs dramatically due to practical considerations:
Administer 500-1000 mg as a single infusion diluted in 250 mL normal saline over 1 hour 1. The guidelines explicitly state it is unreasonable to expect CKD or PD patients to come to a clinic for 10 consecutive weeks to receive small incremental doses 1.
Rationale for Larger Single Doses
The guidelines acknowledge that while hemodialysis patients receive iron conveniently during their thrice-weekly dialysis sessions, non-dialysis patients cannot practically attend multiple weekly infusions 1. Therefore, larger bolus doses (500-1000 mg) are reasonable and necessary, though patients should be informed of increased incidence of myalgias/arthralgias with these higher doses 1.
Safety Considerations
Research supports that 250 mg doses are safe and well-tolerated in non-dialysis CKD patients 3, 4. One study showed 250 mg infused over 1-4 hours had only a 5% side effect rate 4. Higher doses (375-500 mg) have also been administered safely, though more experience is needed 3.
Key Differences Summary
| Population | Dose per Administration | Number of Doses | Total Course | Rationale |
|---|---|---|---|---|
| Hemodialysis | 125 mg (or 62.5 mg) | 8 doses | 1000 mg (or 500 mg) over 8 weeks | Convenient during dialysis sessions; manufacturer limit of 125 mg/dose |
| Non-Dialysis CKD/PD | 500-1000 mg | 1-2 doses | 1000 mg | Impractical for multiple clinic visits |
Monitoring Requirements
- Measure TSAT and ferritin 2-7 days after the last dose for accurate assessment 1
- For doses of 100-125 mg, wait 7 days before checking labs 1
- Do not check iron studies within 14 days of receiving ≥1000 mg IV iron 1
Common Pitfall
The most critical error is applying hemodialysis dosing protocols to non-dialysis patients. The 125 mg maximum per dose is a manufacturer recommendation specific to frequent administration in hemodialysis settings 1. For non-dialysis patients who cannot attend multiple sessions, single larger infusions are both necessary and supported by guidelines 1.